All Stories

  1. Recognizing severe fatigue and decline in quality of life in Hodgkin lymphoma survivors

    Article • Leukemia & Lymphoma, July 2019, Taylor & Francis

    Dr Tamar Tadmor, Estherina Trachtenberg

  2. The prognostic role of end of treatment FDG-PET-CT in patients with diffuse large B cell lymphoma can be improved by considering it with absolute monocyte count at diagnosis

    Article • Leukemia & Lymphoma, January 2019, Taylor & Francis

    stefano sacchi, Dr Tamar Tadmor, MARIA COX

  3. Outcomes of second-line treatment after fludarabine cyclophosphamide and rituximab in patients with chronic lymphocytic leukemia outside clinical trials

    Article • European Journal Of Haematology, August 2018, Wiley

    Dr Lev Shvidel, Dr Tamar Tadmor

  4. Cognitive impairment in hodgkin lymphoma survivors

    Article • British Journal of Haematology, July 2018, Wiley

    Dr Tamar Tadmor

  5. Treatment patterns and clinical outcomes in high-risk newly diagnosed multiple myeloma patients carrying the 17p deletion: An observational multi-center retrospective study

    Article • American Journal of Hematology, April 2018, Wiley

    Dr Tamar Tadmor

  6. Persistently low lymphocyte counts after FCR therapy for chronic lymphocytic leukemia are associated with longer overall survival

    Article • Hematological Oncology, June 2017, Wiley

    Dr Lev Shvidel, Dr Tamar Tadmor

  7. Modification of initial therapy in early and advanced Hodgkin lymphoma, based on interim PET/CT is beneficial: a prospective multicentre trial of 355 patients

    Article • British Journal of Haematology, June 2017, Wiley

    Dr Tamar Tadmor

  8. Severe pneumonia associated with ibrutinib monotherapy for CLL and lymphoma

    Article • Hematological Oncology, February 2017, Wiley

    Dr Tamar Tadmor

  9. Incidence and epidemiology of non-Hodgkin lymphoma and risk of second malignancy among 22 466 survivors in Israel with 30 years of follow-up

    Article • Hematological Oncology, May 2016, Wiley

    Dr Tamar Tadmor

  10. Efficacy and safety of salvage therapy using Carfilzomib for relapsed or refractory multiple myeloma patients: a multicentre retrospective observational study

    Article • British Journal of Haematology, November 2015, Wiley

    Dr Tamar Tadmor, Eli Muchtar

  11. Richter's transformation to diffuse large B-cell lymphoma: A retrospective study reporting clinical data, outcome, and the benefit of adding rituximab to chemotherapy, from the Israeli CLLStudy Group

    Article • American Journal of Hematology, September 2014, Wiley

    Dr Tamar Tadmor